A Novel Synthetic Cannabinoid Derivative Inhibits Inflammatory Liver Damage via Negative Cytokine Regulation

Molecular Pharmacology

Volumn 64, Issue 6, 2003, Pages 1334-1341

  Lavon, Iris ^a   Sheinin, Tatiana ^a   Meilin, Sigal ^a   Biton, Efrat ^a   Weksler, Ayelet ^a   Efroni, Gilat ^a   Bar Joseph, Avi ^a   Fink, George ^a   Avraham, Ayelet ^a  

^a PHARMOS LTD   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

[6,6 DIMETHYL 3 (1,1 DIMETHYLHEPTYL) 1 HYDROXY 9 (1H IMIDAZOL 2 YLSULFANYLMETHYL] 6A,7,10,10A TETRAHYDRO 6H DIBENZO[B,D]PYRAN; CANNABINOID DERIVATIVE; CONCANAVALIN A; CYTOKINE; GAMMA INTERFERON; GENE PRODUCT; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PRS 211092; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; FEMALE; GENE EXPRESSION REGULATION; GENE INDUCTION; HEPATITIS; HUMAN; HUMAN CELL; IMMUNOREGULATION; INFLAMMATION; INFLAMMATORY DISEASE; LIVER INJURY; LIVER PROTECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANNABINOIDS; CONCANAVALIN A; CYTOKINES; FEMALE; HEPATITIS, ANIMAL; MICE; MICE, INBRED BALB C;

EID: 0345735772     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.6.1334     Document Type: Article

References (27)

1. Berdyshev EV (2000) Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 108:169-190.
2. Berlato C, Cassatella MA, Kinjyo I, Gatto L, Yoshimura A, and Bazzoni F (2002) Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. J Immunol 168:6404-6411.
3. Bradham CA, Plumpe J, Manns MP, Brenner DA and Trautwein C (1998) Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am J Physiol 275:G387-G392.
4. Campbell JS, Prichard L, Schaper F, Schmitz J, Stephenson-Famy A, Rosenfeld ME, Argast GM, Heinrich PC, and Fausto N (2001) Expression of suppressors of cytokine signaling during liver regeneration. J Clin Investig 107:1285-1292.
5. Di Marco R, Xiang M, Zaccone P, Leonardi C, Franco S, Meroni P, and Nicoletti F (1999) Concanavalin A-induced hepatitis in mice is prevented by interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency. Autoimmunity 31:75-83.
6. Gantner F, Leist M, Lohse AW, Germann PG, and Tiegs G (1995) Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology 21:190-198.
7. Hong F, Jaruga B, Kim WH, Radaeva S, El-Assal ON, Tian Z, Nguyen VA, and Gao B (2002) Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J Clin Investig 110:1503-1513.
8. Kato M, Ikeda N, Matsushita E, Kaneko S, and Kobayashi K (2001) Involvement of IL-10, an anti-inflammatory cytokine in murine liver injury induced by Concanavalin A. Hepatol Res 20:232-243.
9. Klein TW, Newton CA, and Friedman H (2001) Cannabinoids and the immune system. Pain Res Manag 6:95-101.
10. Koziel MJ (1999) Cytokines in viral hepatitis. Semin Liver Dis 19:157-169.
11. Kusters S, Gantner F, Kunstle G, and Tiegs G (1996) Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 111:462-471.
12. Louis H, Le Moine O, Peny MO, Quertinmont E, Fokan D, Goldman M, and Deviere J (1997) Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice. Hepatology 25:1382-1389.
13. Marine JC, McKay C, Wang D, Topham DJ, Parganas E, Nakajima H, Pendeville H, Yasukawa H, Sasaki A, Yoshimura A, et al. (1999) SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 98:617-627.
14. McFarlane IG (1999) Pathogenesis of autoimmune hepatitis. Biomed Pharmacother 53:255-263.
15. Mechoulam R, Lander N, Breuer A, and Zahalka J (1990) Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative. Tetrahedron Assymetry 1:315-318.
16. Mechoulam R (2000) Looking back at cannabis research. Curr Pharm Des 6:1313-1322.
17. Mizuhara H, O'Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K, Satoh S, Niwa M, Senoh H, and Fujiwara H (1994) T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 179:1529-1537.
18. Mizuhara H, Uno M, Seki N, Yamashita M, Yamaoka M, Ogawa T, Kaneda K, Fujii T, Senoh H, and Fujiwara H (1996) Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis. Hepatology 23:1608-1615.
19. Nelson DR, Lauwers GY, Lau JY, and Davis GL (2000) Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 118:655-660.
20. Sass G, Heinlein S, Agli A, Bang R, Schumann J, and Tiegs G (2002) Cytokine expression in three mouse models of experimental hepatitis. Cytokine 19:115-120.
21. Shen X, Hong F, Nguyen VA, and Gao B (2000) IL-10 attenuates IFN-alpha-activated STAT1 in the liver: involvement of SOCS2 and SOCS3. FEBS Lett 480:132-136.
22. Starr R, Metcalf D, Elefanty AG, Brysha M, Willson TA, Nicola NA, Hilton DJ, and Alexander WS (1998) Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci USA 95:14395-14399.
23. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, et al. (1997) A family of cytokine-inducible inhibitors of signalling. Nature (Lond) 387:917-921.
24. Tagawa Y, Matthys P, Heremans H, Dillen C, Zaman Z, Iwakura Y, and Billiau A (2000) Bimodal role of endogenous interleukin-6 in concanavalin A-induced hepatitis in mice. J Leukoc Biol 67:90-96.
25. Tiegs G, Hentschel J, and Wendel A (1992) A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Investig 90:196-203.
26. Yasukawa H, Sasaki A, and Yoshimura A (2000) Negative regulation of cytokine signaling pathways. Annu Rev Immunol 18:143-164.
27. Yokochi S, Hashimoto H, Ishiwata Y, Shimokawa H, Haino M, Terashima Y, and Matsushima K (2001) An anti-inflammatory drug, propagermanium, may target GPI-anchored proteins associated with an MCP-1 receptor, CCR2. J Interferon Cytokine Res 21:389-398.